Search research articles
Contact Us
Filters
Showing results (61-70 of 90) with videos related to
Page
of 9
Sort By:
Haematologica
|
November 30, 2023
Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma
Matthew J Maurer, Carla Casulo, Melissa C Larson, et al.
Blood
|
March 10, 2019
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
Andrew D Zelenetz, Gilles Salles, Kylie D Mason, et al.
The Lancet. Haematology
|
March 31, 2022
Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study
Carla Casulo, Melissa C Larson, Julianne J Lunde, et al.
Blood
|
October 25, 2023
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)
Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2025
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826
Sarah C Rutherford, Hongli Li, Alex F Herrera, et al.
The Lancet. Oncology
|
December 13, 2021
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
Caron A Jacobson, Julio C Chavez, Alison R Sehgal, et al.
Hematological Oncology
|
October 7, 2025
Adaptation and Performance of the Self-Report-Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort
James R Cerhan, Tereza Sokolova, Elliott J Cahn, et al.
Transplantation and Cellular Therapy
|
July 7, 2024
Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation
Madiha Iqbal, Ambuj Kumar, Peter Dreger, et al.
Blood Advances
|
December 3, 2025
Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop
Reid W Merryman, Sarah C Rutherford, Stephen M Ansell, et al.
Blood Advances
|
January 31, 2022
Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey
R Andrew Harkins, Sharvil P Patel, Michelle J Lee, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 90) with videos related to
Sort By:
Page
of 9
Haematologica
|
November 30, 2023
Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma
Matthew J Maurer, Carla Casulo, Melissa C Larson, et al.
Blood
|
March 10, 2019
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
Andrew D Zelenetz, Gilles Salles, Kylie D Mason, et al.
The Lancet. Haematology
|
March 31, 2022
Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study
Carla Casulo, Melissa C Larson, Julianne J Lunde, et al.
Blood
|
October 25, 2023
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)
Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2025
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826
Sarah C Rutherford, Hongli Li, Alex F Herrera, et al.
The Lancet. Oncology
|
December 13, 2021
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
Caron A Jacobson, Julio C Chavez, Alison R Sehgal, et al.
Hematological Oncology
|
October 7, 2025
Adaptation and Performance of the Self-Report-Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort
James R Cerhan, Tereza Sokolova, Elliott J Cahn, et al.
Transplantation and Cellular Therapy
|
July 7, 2024
Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation
Madiha Iqbal, Ambuj Kumar, Peter Dreger, et al.
Blood Advances
|
December 3, 2025
Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop
Reid W Merryman, Sarah C Rutherford, Stephen M Ansell, et al.
Blood Advances
|
January 31, 2022
Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey
R Andrew Harkins, Sharvil P Patel, Michelle J Lee, et al.
Page
of 9